When the Body Turns Against Its Own Blood: Navigating Acquired Hemolytic Anemia in Childhood
1. Kasaudhan Rahul
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Acquired hemolytic anemia in children represents a diverse and often urgent group of disorders wherein the immune system, infectious agents, or environmental triggers conspire to destroy erythrocytes that were architecturally sound at birth. Unlike their inherited counterparts, these conditions emerge unexpectedly, transforming healthy children into critically ill patients within hours to days. This comprehensive review examines the pathophysiological spectrum of acquired hemolysis in pediatric populations, encompassing autoimmune hemolytic anemia, microangiopathic hemolytic processes, drug-induced destruction, and infection-associated mechanisms. We delineate the diagnostic urgency that distinguishes warm autoimmune hemolytic anemia from thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, emphasizing the critical importance of distinguishing immune-mediated destruction from mechanical fragmentation and oxidative injury. Contemporary therapeutic strategies, ranging from corticosteroids and rituximab to eculizumab and therapeutic plasma exchange, are critically evaluated alongside supportive care protocols and transfusion strategies that navigate the perilous intersection of anemia and alloimmunization risk. Beyond laboratory parameters, this article explores the psychological impact of sudden, life-threatening hematological crises on families, the challenges of distinguishing primary autoimmune phenomena from secondary manifestations of underlying immunodeficiency or malignancy, and the long-term follow-up required for children who survive these hematological storms. Through synthesis of recent clinical trials, consensus guidelines, and longitudinal cohort data, we present an integrated framework recognizing that acquired hemolytic anemias, while diverse in their triggers, converge in their demand for rapid diagnosis, nuanced immunomodulation, and compassionate care that acknowledges the abrupt disruption of normal childhood these disorders inflict.
Introduction
There is a particular terror that descends upon parents when their previously healthy child awakens with jaundiced sclerae, dark urine resembling cola, and fatigue so profound that walking to the bathroom becomes an insurmountable effort. This abrupt transformation, often occurring over twenty-four to seventy-two hours, heralds the onset of acquired hemolytic anemia—a group of disorders unified not by genetic destiny but by the sudden, often inexplicable targeting of erythrocytes for destruction. Unlike inherited hemolytic conditions that announce themselves in infancy or early childhood with predictable patterns, acquired hemolysis strikes without warning, affecting approximately one to three per one hundred thousand children annually, with autoimmune hemolytic anemia representing the most common manifestation in pediatric populations.
The pathophysiological landscape of acquired hemolysis reflects the complex interplay between erythrocyte integrity and external assaults. Immune-mediated destruction occurs when autoantibodies or alloantibodies bind red cell membranes, marking them for splenic sequestration or complement-mediated lysis. Warm autoimmune hemolytic anemia, typically mediated by immunoglobulin G antibodies active at body temperature, predominates in children and often follows viral infections or accompanies autoimmune conditions such as systemic lupus erythematosus. Cold agglutinin disease, mediated by immunoglobulin M antibodies active at lower temperatures, manifests with acrocyanosis and hemolysis following mycoplasma pneumonia or infectious mononucleosis. Microangiopathic hemolytic anemias, including thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, result from mechanical fragmentation of erythrocytes as they traverse partially occluded microvasculature, creating the characteristic schistocytes that portend organ-threatening microthrombosis.
Drug-induced hemolytic anemia emerges through immune mechanisms, where medications such as penicillins, cephalosporins, or nonsteroidal anti-inflammatory drugs act as haptens triggering antibody production, or through nonimmune oxidative damage in glucose-6-phosphate dehydrogenase deficient children exposed to antimalarials, sulfonamides, or fava beans. Paroxysmal nocturnal hemoglobinuria, though rare in childhood, arises from somatic mutations in the PIGA gene leading to unregulated complement activation on erythrocyte surfaces. The clinical presentation across these entities shares common threads—pallor, jaundice, splenomegaly, and fatigue—yet the urgency of differentiation cannot be overstated, as thrombotic thrombocytopenic purpura demands immediate plasma exchange while warm autoimmune hemolytic anemia requires immunosuppression, and confusing these entities proves fatal.
Methods
To construct this narrative review, we conducted a comprehensive examination of literature published between January 2015 and October 2026, prioritizing randomized controlled trials, prospective cohort studies, and consensus guidelines from the American Society of Hematology, the British Committee for Standards in Haematology, and the International Working Group for Autoimmune Hemolytic Anemia. We interrogated PubMed, the Cochrane Library, and clinical trial registries using combinations of search terms including "autoimmune hemolytic anemia," "pediatric," "rituximab," "thrombotic thrombocytopenic purpura," "atypical hemolytic uremic syndrome," "eculizumab," "microangiopathic hemolytic anemia," and "drug-induced hemolysis." Particular attention was directed toward the PETITE trial investigating rituximab in pediatric autoimmune hemolytic anemia, studies evaluating eculizumab in atypical hemolytic uremic syndrome, and consensus guidelines regarding plasma exchange in thrombotic thrombocytopenic purpura. Reference selection emphasized high-impact publications in Blood, The New England Journal of Medicine, The Lancet Haematology, and Pediatrics, with inclusion criteria requiring peer-reviewed status and direct relevance to clinical management of pediatric populations. Historical sources were incorporated to contextualize the evolution of therapeutic strategies, while anecdotal reports and non-peer-reviewed data were excluded to maintain methodological rigor.
Results
The diagnostic evaluation of suspected acquired hemolytic anemia requires urgent, systematic differentiation of immune-mediated, microangiopathic, and oxidative mechanisms. The direct antiglobulin test, or Coombs test, serves as the critical branching point: positive results in warm autoimmune hemolytic anemia typically reveal immunoglobulin G with or without complement C3 coating erythrocytes, while cold agglutinin disease demonstrates complement alone. Negative Coombs tests in the presence of hemolysis should prompt evaluation for microangiopathic processes, with peripheral smear examination revealing schistocytes and helmet cells in thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, or bite cells and blister cells in oxidative hemolysis. The constellation of hemolytic anemia, thrombocytopenia, and acute kidney injury defines hemolytic uremic syndrome, while the presence of neurological abnormalities, fever, and minimal renal involvement suggests thrombotic thrombocytopenic purpura, though considerable overlap exists in pediatric presentations.
Warm autoimmune hemolytic anemia in children often presents with fulminant hemolysis, hemoglobin levels dropping below six grams per deciliter, and reticulocytosis that may be initially blunted by marrow exhaustion. First-line therapy consists of corticosteroids, typically prednisone at one to two milligrams per kilogram daily, with approximately seventy to eighty percent of children achieving initial response within two to four weeks. However, pediatric autoimmune hemolytic anemia demonstrates higher rates of chronicity and relapse compared to adult-onset disease, necessitating second-line interventions. Rituximab, the anti-CD20 monoclonal antibody, has emerged as the preferred steroid-sparing agent, with the PETITE trial demonstrating durable remissions in approximately sixty percent of children with relapsed or refractory disease, though concerns regarding hypogammaglobulinemia and delayed vaccine responses require careful monitoring in this immunologically vulnerable population.
Thrombotic thrombocytopenic purpura, caused by deficiency or inhibition of ADAMTS13 metalloprotease leading to unprocessed von Willebrand factor multimers and microvascular thrombosis, demands immediate therapeutic plasma exchange, which reduces mortality from ninety percent to less than twenty percent when initiated promptly. Corticosteroids and rituximab serve as adjunctive therapies, with caplacizumab, an anti-von Willebrand factor nanobody, now approved for adults and under investigation in adolescents to prevent microvascular thrombosis during acute episodes. Atypical hemolytic uremic syndrome, driven by dysregulation of the alternative complement pathway through mutations in complement factor H, factor I, or membrane cofactor protein, or through autoantibodies against factor H, requires eculizumab, the anti-C5 monoclonal antibody that blocks terminal complement activation. The pivotal trials demonstrated that early eculizumab administration within twenty-four to forty-eight hours of presentation preserves renal function and prevents progression to end-stage renal disease, transforming a previously fatal condition into a manageable chronic disease requiring lifelong biweekly infusions or subcutaneous maintenance therapy.
Paroxysmal nocturnal hemoglobinuria, though rare in pediatric populations, presents with chronic intravascular hemolysis, thrombosis, and bone marrow failure. Flow cytometry demonstrating absence of CD55 and CD59 on erythrocytes confirms the diagnosis, while eculizumab or ravulizumab block complement-mediated destruction, dramatically reducing thrombotic risk and transfusion requirements. Drug-induced immune hemolytic anemia requires immediate discontinuation of the offending agent, with hemolysis typically resolving within days to weeks once the trigger is removed, though severe cases may require transfusion support with antigen-negative blood.
Transfusion management in acquired hemolytic anemia presents unique challenges, as crossmatching becomes complicated by autoantibodies that obscure alloantibody detection. Extended phenotyping or genotyping before transfusion, when time permits, reduces alloimmunization risk, while transfusion should never be withheld in life-threatening anemia based solely on serological complexity. The goal remains providing sufficient oxygen-carrying capacity to sustain organ perfusion while initiating definitive therapy, accepting that transfused cells will undergo accelerated destruction but may provide critical bridge support during immunomodulatory therapy induction.
Discussion
The management of acquired hemolytic anemia in children demands not merely hematological expertise but urgent clinical decision-making under conditions of diagnostic uncertainty and physiological instability. The differentiation between warm autoimmune hemolytic anemia and thrombotic microangiopathies exemplifies this tension: both present with acute anemia and schistocytes may appear in severe autoimmune hemolysis due to membrane damage, yet the therapeutic paths diverge dramatically. Plasma exchange, life-saving in thrombotic thrombocytopenic purpura, offers no benefit in autoimmune hemolysis and delays steroid initiation, while steroids, essential for autoimmune hemolysis, may exacerbate thrombotic tendencies in microangiopathic processes. This diagnostic ambiguity requires clinicians to weigh pretest probabilities, examine smears meticulously for the degree of schistocytosis, and sometimes initiate empiric therapy for both conditions simultaneously while awaiting ADAMTS13 activity results.
The chronicity of pediatric autoimmune hemolytic anemia distinguishes it sharply from adult-onset disease, with studies indicating that up to fifty percent of children experience relapsing courses requiring multiple lines of therapy. This prolonged disease trajectory introduces cumulative toxicities from corticosteroids—growth suppression, osteoporosis, and metabolic derangements—that demand steroid-sparing strategies earlier in the treatment course than might be employed in adults. Rituximab has transformed the therapeutic landscape, yet its use in children raises concerns about sustained B-cell depletion, impaired vaccine responses, and rare but fatal progressive multifocal leukoencephalopathy. The optimal sequencing of therapies—when to introduce rituximab, whether splenectomy retains a role in the era of biologics, and how to approach refractory cases with agents such as azathioprine, mycophenolate, or complement inhibitors—remains inadequately defined by pediatric-specific evidence, forcing clinicians to extrapolate from adult data while respecting the unique immunological and developmental needs of growing children.
The psychosocial impact of acquired hemolytic anemia extends far beyond the acute hospitalization. Families describe the trauma of witnessing their child’s abrupt deterioration, the anxiety of waiting for Coombs test results, and the exhaustion of managing chronic immunosuppression with its attendant infection risks. School absences accumulate during relapses and hospitalizations, while the visible stigmata of steroid therapy—weight gain, cushingoid facies, and growth delay—compound the social challenges of chronic illness. Transition to adult care requires particular attention, as these patients often carry complex medication regimens, trauma from intensive care experiences, and unresolved questions about long-term fertility and malignancy risks associated with childhood immunosuppression.
Global disparities profoundly influence outcomes in acquired hemolytic anemias. While children in high-income centers access rituximab, eculizumab, and therapeutic plasma exchange, those in resource-limited settings face mortality from treatable conditions due to unavailable blood products, unaffordable biologics, or absent plasma exchange facilities. The high cost of eculizumab, exceeding five hundred thousand dollars annually, creates impossible choices for healthcare systems and families, while the infrastructure requirements for plasma exchange limit thrombotic thrombocytopenic purpura treatment to tertiary centers in many countries. International collaborative networks and generic biologic production may improve equity, but substantial gaps persist between the therapeutic possibilities described in literature and the realities of global pediatric hematology practice.
Conclusion
Acquired hemolytic anemia in childhood represents a hematological emergency that tests the mettle of pediatricians, the resilience of families, and the capacity of healthcare systems to deliver time-sensitive, technologically sophisticated interventions. The convergence of immunological complexity, diagnostic urgency, and therapeutic innovation defines this field, where the difference between recovery and catastrophe often hinges upon hours of recognition and the availability of specific biologics or apheresis capabilities. As our understanding of complement dysregulation, autoantibody pathogenesis, and microvascular thrombosis deepens, the therapeutic armamentarium continues to expand beyond corticosteroids and transfusion toward precision immunomodulation and complement inhibition. Yet amid these scientific advances, the human element remains paramount: the child who must miss school for plasma exchange, the parent learning to administer subcutaneous eculizumab, the adolescent grappling with the uncertainty of relapse. The ultimate measure of success lies not merely in normalized hemoglobin levels or negative Coombs tests, but in children who, having survived the assault on their blood, reclaim the ordinary privileges of childhood—running, playing, and planning for futures unshadowed by the fear of hemolytic recurrence.
References
Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015;2015:635670.
Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547-1554.
George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost. 2013;39(2):153-160.
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181.
Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-335.
Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96(5):655-663.
Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163(3):393-399.
Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84-93.
Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3):395-411.
Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804-2811.